Oral drug therapy for erectile dysfunction: Overview and aeromedical implications

Alon Grossman*, Erez Barenboim, Bella Azaria, Yaniv Sherer, Liav Goldstein

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Approximately 150 million men worldwide experience erectile dysfunction, whereby they are unable to maintain an erection adequate for satisfactory sexual performance. This population is projected to more than double in the next 25 yr. Introduction of the phosphodiesterase inhibitors has revolutionized the management of this common problem, encouraging many more men to seek treatment. The issue of erectile dysfunction treatment is a growing concern in the aviation community as well. This is particularly relevant in civil aviation, as this population is older and has co-morbidities that may contribute to the development of erectile dysfunction. In this article we will review the available options for oral treatment of erectile dysfunction and discuss implications regarding their use in aviators based on the information available in the literature.

Original languageEnglish
Pages (from-to)997-1000
Number of pages4
JournalAviation Space and Environmental Medicine
Volume75
Issue number11
StatePublished - Nov 2004
Externally publishedYes

Keywords

  • Aerospace medicine
  • Aviators
  • Erectile dysfunction
  • Sildenafil
  • Tadalafil
  • Vardenafil

Fingerprint

Dive into the research topics of 'Oral drug therapy for erectile dysfunction: Overview and aeromedical implications'. Together they form a unique fingerprint.

Cite this